Post Date December, 03 2023
In traditional Chinese medicine theory, the syndrome of BPH is Qi deficiency and blood stasis, which means that Qi deficiency and blood stasis syndrome is the pathogenic source of BPH. Spleen and kidney deficiency is an important cause of prostate hyperplasia. Spleen and kidney qi deficiency leads to blood stasis, blood stasis and residual essence stagnation in the prostate, and prostate hyperplasia occurs.
In the treatment of patients with benign prostatic hyperplasia due to deficiency of spleen and kidney qi, it is necessary to use drugs that replenish qi and yang to replenish the body's positive qi and smooth the spleen, thereby improving the overall body's operational absorption and digestive functions, balancing and coordinating the functions of the five viscera and six internal organs, and achieving the goal of strengthening the foundation and strengthening the health. "Failure to maintain qi deficiency can effectively avoid the syndrome of blood stasis induced by qi deficiency, and will not cause the prostate to continue to grow.".
Drugs that replenish qi and yang can effectively improve men's sexual function, eliminate the inability of men to absorb digestive and reproductive system secretions and blood stasis due to deficiency of spleen and kidney qi, and block the source of prostate hyperplasia. In the theory of traditional Chinese medicine, qi and blood are mutually reinforcing, and yin and yang are mutually rooted. To replenish qi, it is necessary to nourish blood, and to replenish yang, it is necessary to supplement yin. During treatment, you can choose drugs such as astragalus and ginseng to nourish vital energy, consolidate the root and stop deficiency, and improve body functions. It can be combined with Xianling spleen to replenish qi and yang, wolfberry to nourish yin and latent yang, and mulberry and seabuckthorn can also be added to nourish yin and blood. Various drugs work together to strengthen the spleen and kidney, invigorate the yang, eliminate the deficiency syndrome in patients, and block the pathogenic source of prostate hyperplasia.
